Stay updated on Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial page.

Latest updates to the Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study record is now available, with details on the completed trial of a helper peptide vaccine plus pembrolizumab for melanoma, including eligibility criteria, study measures, and a protocol document. Previously, the page displayed a forbidden-access error.SummaryDifference52%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide notice announces an NIH website transition and says that some NIH content will use “Super Intelligence” in place of “Artificial Intelligence”.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov footer revision updated from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating the page is currently inaccessible.SummaryDifference19%

Stay in the know with updates to Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial page.